文献速递基础与转化研究临床试验与 GCP

自体体外慢病毒基因治疗腺苷脱氨酶缺陷症

Autologous Ex Vivo Lentiviral Gene Therapy for Adenosine Deaminase Deficiency.
PubMed 文献 · N Engl J Med · 2021-05-11

该研究对50例ADA-SCID患者(美国30例,英国20例)采用自体CD34+造血干/祖细胞体外慢病毒载体基因治疗。随访24-36个月,总生存率100%,无事件生存率美国研究97%(12个月)和97%(24个月),英国研究100%(12个月)、95%(24个月)和95%(36个月)。基因修饰细胞持续植入,代谢纠正和免疫重建良好,无严重不良事件。

要点

  • 自体体外慢病毒基因治疗ADA-SCID可实现100%总生存。
  • 无事件生存率美国研究12个月97%,24个月97%;英国研究12个月100%,24个月95%,36个月95%。
  • 90%美国患者和100%英国患者在24和36个月时停止免疫球蛋白替代治疗。

核心结论

  • 自体体外慢病毒造血干/祖细胞基因治疗ADA-SCID获得高总生存率和无事件生存率,伴有持续ADA表达、代谢纠正和功能性免疫重建。

研究设计与样本

  • 研究治疗50例ADA-SCID患者(美国30例,英国20例),采用自体CD34+造血干/祖细胞体外慢病毒载体转导人ADA基因。
  • 美国研究使用新鲜和冷冻保存制剂,随访24个月;英国研究使用新鲜制剂,随访36个月。

主要发现

  • 所有研究至24和36个月总生存率均为100%。
  • 无事件生存率(无酶替代治疗重启或挽救性异基因造血干细胞移植)美国研究12个月97%、24个月97%;英国研究12个月100%、24个月95%、36个月95%。
  • 基因修饰造血干/祖细胞植入持续存在于美国研究30例中的29例和英国研究20例中的19例。
  • 患者代谢持续解毒和ADA活性水平正常化;免疫重建稳健,美国研究90%和英国研究100%的患者分别在24和36个月时停止免疫球蛋白替代治疗。
  • 未观察到单克隆扩增、淋巴增殖性并发症或复制 competent 慢病毒出现,无自身免疫或移植物抗宿主病事件;大多数不良事件为低级别。

临床怎么用

  • 对于ADA-SCID患者,自体体外慢病毒基因治疗可作为潜在治疗选择,可实现高生存率和免疫重建,避免酶替代治疗和异基因移植相关风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Severe combined immunodeficiency due to adenosine deaminase (ADA) deficiency (ADA-SCID) is a rare and life-threatening primary immunodeficiency. METHODS: We treated 50 patients with ADA-SCID (30 in the United States and 20 in the United Kingdom) with an investigational gene therapy composed of autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) transduced ex vivo with a self-inactivating lentiviral vector encoding human ADA. Data from the two U.S. studies (in which fresh and cryopreserved formulations were used) at 24 months of follow-up were analyzed alongside data from the U.K. study (in which a fresh formulation was used) at 36 months of follow-up. RESULTS: Overall survival was 100% in all studies up to 24 and 36 months. Event-free survival (in the absence of reinitiation of enzyme-replacement therapy or rescue allogeneic hematopoietic stem-cell transplantation) was 97% (U.S. studies) and 100% (U.K. study) at 12 months; 97% and 95%, respectively, at 24 months; and 95% (U.K. study) at 36 months. Engraftment of genetically modified HSPCs persisted in 29 of 30 patients in the U.S. studies and in 19 of 20 patients in the U.K. study. Patients had sustained metabolic detoxification and normalization of ADA activity levels. Immune reconstitution was robust, with 90% of the patients in the U.S. studies and 100% of those in the U.K. study discontinuing immunoglobulin-replacement therapy by 24 months and 36 months, respectively. No evidence of monoclonal expansion, leukoproliferative complications, or emergence of replication-competent lentivirus was noted, and no events of autoimmunity or graft-versus-host disease occurred. Most adverse events were of low grade. CONCLUSIONS: Treatment of ADA-SCID with ex vivo lentiviral HSPC gene therapy resulted in high overall and event-free survival with sustained ADA expression, metabolic correction, and functional immune reconstitution. (Funded by the National Institutes of Health and others; ClinicalTrials.gov numbers, NCT01852071, NCT02999984, and NCT01380990.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Kohn DB, Booth C, Shaw KL, et al. Autologous Ex Vivo Lentiviral Gene Therapy for Adenosine Deaminase Deficiency. N Engl J Med. 2021. PMID: 33974366. doi:10.1056/NEJMoa2027675

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。